New Zealand markets close in 46 minutes

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8963-0.0074 (-0.82%)
At close: 04:00PM EDT
0.8700 -0.03 (-2.93%)
After hours: 05:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 27.35M
Enterprise value -87.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.90
Price/book (mrq)0.44
Enterprise value/revenue -5.06
Enterprise value/EBITDA 0.81

Trading information

Stock price history

Beta (5Y monthly) 1.94
52-week change 3-93.32%
S&P500 52-week change 3-2.16%
52-week high 319.8700
52-week low 30.6800
50-day moving average 30.8561
200-day moving average 37.5623

Share statistics

Avg vol (3-month) 3330.38k
Avg vol (10-day) 3317.52k
Shares outstanding 535.07M
Implied shares outstanding 6N/A
Float 827.3M
% held by insiders 115.00%
% held by institutions 159.42%
Shares short (28 Jul 2022) 4406.07k
Short ratio (28 Jul 2022) 42.03
Short % of float (28 Jul 2022) 41.36%
Short % of shares outstanding (28 Jul 2022) 41.16%
Shares short (prior month 29 Jun 2022) 4413.57k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-957.08%

Management effectiveness

Return on assets (ttm)-64.45%
Return on equity (ttm)-179.55%

Income statement

Revenue (ttm)9.87M
Revenue per share (ttm)0.30
Quarterly revenue growth (yoy)-61.30%
Gross profit (ttm)-42.11M
EBITDA -93.64M
Net income avi to common (ttm)-113.27M
Diluted EPS (ttm)-3.2550
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)45.4M
Total cash per share (mrq)1.29
Total debt (mrq)7M
Total debt/equity (mrq)19.49
Current ratio (mrq)3.65
Book value per share (mrq)1.02

Cash flow statement

Operating cash flow (ttm)-83.56M
Levered free cash flow (ttm)-49.85M